Study to Expand Safety and Immunogenicity Data With Shigella Bioconjugate Vaccine (Shigella4V2) in 9-month-old Infants.

NCT06523231 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Shigellosis

Interventions

BIOLOGICAL: Shigella4V2
BIOLOGICAL: MenACWY

Sponsor

LimmaTech Biologics AG

Collaborators

[object Object]